Page 1 | Search Results | Blood | American Society of Hematology

1-10 of 10

Sort by

Sort Order Select

Journal Articles

A Novel Sequential Treatment Utilizing CPX-351 As Salvage Chemotherapy Followed by a Reduced Intensity Conditioning Allogeneic Stem-Cell Transplantation for Patients with Refractory Leukemia

Usama Gergis, MD, Gail J. Roboz, MD, Ellen Ritchie, MD, Joseph M. Scandura, MD, PhD, Karen-Sue B. Carlson, MD, PhD, Tsiporah B. Shore, MD, Sebastian Mayer, MD, Tomer M Mark, MD, MSc, Roger N Pearse, MD, PhD, June Greenberg, Tania J Curcio, R.N, Cindy Ippoliti, PharmD, Marshall McKenna, Eric J Feldman, MD

Blood (2011) 118 (21): 3030.

https://doi.org/10.1182/blood.V118.21.3030.3030

Published: 2011

Journal Articles

Epigenetic Priming with Decitabine Prior to Standard Induction Chemotherapy in Less-Than-Favorable Risk Acute Myelogenous Leukemia (AML).

Joseph M. Scandura, MD, PhD, Gail J. Roboz, MD, Michelle Moh, MS, Jahar R Bose, Usama S Gergis, MD, Sebastian A Mayer, MD, Cindy Ippoliti, PharmD, Curcio J Tania, RN, Ellen K Ritchie, MD, Eric J. Feldman, MD

Blood (2009) 114 (22): 3079.

https://doi.org/10.1182/blood.V114.22.3079.3079

Published: 2009

Journal Articles

Decitabine-Based Salvage Therapy in Adults with Acute Myeloid Leukemia.

Ellen K Ritchie, MD, Jon Arnason, MD, Eric J. Feldman, MD, Usama S Gergis, MD, Sebastian A Mayer, MD, Cindy Ippoliti, PharmD, Joseph M. Scandura, MD, PhD, Gail Roboz, MD

Blood (2009) 114 (22): 2063.

https://doi.org/10.1182/blood.V114.22.2063.2063

Published: 2009

Journal Articles

Campath-IH Combined with Fludarabine/Cyclophophamide/Rituximab (FCR) as Conditioning for Unrelated Non-Myeloablative Hematopoietic Transplantation (NMT) for Non-Hodgkin’s Lymphoma (NHL): Low Mortality Rate and Lower Than Expected Incidence of Cytomegalovirus (CMV) Reactivation.

Issa F. Khouri, MD, Jeffrey J. Tarrand, MD, Grace-Julia Okoroji, MS, Rima M. Saliba, PhD, Chitra M. Hosing, MD, Daniel R. Couriel, MD, Partow Kebriaei, MD, Donna Griffith, RN, Gabriela Rondon, MD, Cindy Ippoliti, PharmD, Richard E. Champlin, MD

Blood (2005) 106 (11): 2902.

https://doi.org/10.1182/blood.V106.11.2902.2902

Published: 2005

Journal Articles

Allogeneic Transplantation after an Alemtuzumab-Containing Myeloablative Conditioning Regimen for CD52 Positive Acute Lymphoblastic Leukemia (ALL).

Partow Kebriaei, MD, Rima M. Saliba, PhD, Carrie Ma, Cindy Ippoliti, PharmD, Daniel R. Couriel, MD, Marcos de Lima, MD, Sergio Giralt, MD, Muzaffar H. Qazilbash, MD, James L. Gajewski, MD, Chul S. Ha, MD, Richard E. Champlin, MD, Issa F. Khouri, MD

Blood (2005) 106 (11): 1135.

https://doi.org/10.1182/blood.V106.11.1135.1135

Published: 2005

Journal Articles

Clinical, Prognostic and Therapeutic Implications in the Diagnosis of Grade I Acute Graft-Versus-Host Disease.

Rima M. Saliba, PhD, Marcos de Lima, MD, Chitra Hosing, MD, Issa F. Khouri, MD, Sergio Giralt, MD, Paolo Anderlini, MD, Shubhra Ghosh, MD, Kerry Mickler, RN, Cindy Ippoliti, PHARMD, Zuraima Caldera, MD, Yvonne Hsu, PAC, Joyce Neumann, APN, Richard Champlin, MD, Daniel R. Couriel, MD

Blood (2005) 106 (11): 1799.

https://doi.org/10.1182/blood.V106.11.1799.1799

Published: 2005

Journal Articles

The Impact of Rituximab in the Development of Acute Graft Versus Host Disease (GVHD) Following Allogeneic Stem Cell Transplantation (SCT) for Acute Lymphoblastic Leukemia (ALL).

Partow Kebriaei, MD, Rima M. Saliba, PhD, Carrie Ma, Cindy Ippoliti, PharmD, Daniel R. Couriel, MD, Marcus de Lima, MD, Sergio Giralt, MD, Muzaffar H. Qazilbash, MD, James L. Gajewski, MD, Chul S. Ha, MD, Richard E. Champlin, MD, Issa F. Khouri, MD

Blood (2005) 106 (11): 1803.

https://doi.org/10.1182/blood.V106.11.1803.1803

Published: 2005

Journal Articles

Phase II/III Randomized Study Comparing Two Different Tacrolimus Blood Levels for the Prevention of Graft-Versus-Host Disease (GVHD).

Daniel R. Couriel, MD, Peter Thall, PhD, Kerry Mickler, RN, Marcos De Lima, MD, Sergio Giralt, MD, Muzaffar H. Qazilbash, MD, Chitra Hosing, MD, Issa Khouri, MD, Partow Kebriaei, MD, Yvonne Hsu, MD, Rima Saliba, MD, Cindy Ippoliti, PharmD, Richard Champlin, MD

Blood (2005) 106 (11): 142.

https://doi.org/10.1182/blood.V106.11.142.142

Published: 2005

Journal Articles

Allogeneic Transplantation for Adult Acute Lymphoblastic Leukemia (ALL) with Rituximab or Campath I-H.

Issa F. Khouri, MD, Rima M. Saliba, PhD, Partow Kebriaei, MD, Carrie Ma, Cindy Ippoliti, PharmD, Daniel R. Couriel, MD, Marcus de Lima, MD, Sergio Giralt, MD, Muzaffar H. Qazilbash, MD, James L. Gajewski, MD, Richard E. Champlin, MD

Blood (2004) 104 (11): 5132.

https://doi.org/10.1182/blood.V104.11.5132.5132

Published: 2004

Journal Articles

Allogeneic Stem Cell Transplantation with Reduced-Intensity, Fludarabine-Based Conditioning in Relapsed and Refractory Hodgkin’s Disease: Low Transplant-Related Mortality and Impact of Intensity of Conditioning Regimen on Survival.

Paolo Anderlini, MD, Rima Saliba, PhD, Michele Donato, MD, Sergio Giralt, MD, Borje Andersson, MD, Nato T. Ueno, MD, Issa F. Khouri, MD, Marcos de Lima, MD, Cindy Ippoliti, PharmD, Richard E. Champlin, MD

Blood (2004) 104 (11): 2135.

https://doi.org/10.1182/blood.V104.11.2135.2135

Published: 2004

NARROW

A Novel Sequential Treatment Utilizing CPX-351 As Salvage Chemotherapy Followed by a Reduced Intensity Conditioning Allogeneic Stem-Cell Transplantation for Patients with Refractory Leukemia

Epigenetic Priming with Decitabine Prior to Standard Induction Chemotherapy in Less-Than-Favorable Risk Acute Myelogenous Leukemia (AML).

Decitabine-Based Salvage Therapy in Adults with Acute Myeloid Leukemia.

Campath-IH Combined with Fludarabine/Cyclophophamide/Rituximab (FCR) as Conditioning for Unrelated Non-Myeloablative Hematopoietic Transplantation (NMT) for Non-Hodgkin’s Lymphoma (NHL): Low Mortality Rate and Lower Than Expected Incidence of Cytomegalovirus (CMV) Reactivation.

Allogeneic Transplantation after an Alemtuzumab-Containing Myeloablative Conditioning Regimen for CD52 Positive Acute Lymphoblastic Leukemia (ALL).

Clinical, Prognostic and Therapeutic Implications in the Diagnosis of Grade I Acute Graft-Versus-Host Disease.

The Impact of Rituximab in the Development of Acute Graft Versus Host Disease (GVHD) Following Allogeneic Stem Cell Transplantation (SCT) for Acute Lymphoblastic Leukemia (ALL).

Phase II/III Randomized Study Comparing Two Different Tacrolimus Blood Levels for the Prevention of Graft-Versus-Host Disease (GVHD).

Allogeneic Transplantation for Adult Acute Lymphoblastic Leukemia (ALL) with Rituximab or Campath I-H.

Allogeneic Stem Cell Transplantation with Reduced-Intensity, Fludarabine-Based Conditioning in Relapsed and Refractory Hodgkin’s Disease: Low Transplant-Related Mortality and Impact of Intensity of Conditioning Regimen on Survival.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only